PetVivo Holdings, Inc. (PETV)
USD 0.63
(4.99%)
USD 0.63
(4.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -10.95 Million USD | -25.9% |
| 2023 | -8.7 Million USD | -76.09% |
| 2022 | -4.94 Million USD | -31.73% |
| 2021 | -3.75 Million USD | -77.38% |
| 2020 | -2.11 Million USD | 55.55% |
| 2019 | -4.75 Million USD | -103.55% |
| 2018 | -2.33 Million USD | 84.95% |
| 2017 | -15.53 Million USD | -325.32% |
| 2016 | -3.65 Million USD | -133.24% |
| 2015 | -1.56 Million USD | 95.77% |
| 2014 | -36.99 Million USD | -42810.07% |
| 2013 | -86.21 Thousand USD | 16.0% |
| 2012 | -102.63 Thousand USD | 61.04% |
| 2011 | -263.44 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -10.95 Million USD | -25.9% |
| 2024 Q1 | -2.89 Million USD | -24.24% |
| 2024 Q2 | -3.66 Million USD | -26.53% |
| 2024 Q4 | -2.65 Million USD | -51.48% |
| 2024 Q3 | -1.74 Million USD | 52.21% |
| 2023 Q4 | -2.32 Million USD | -1.07% |
| 2023 Q3 | -2.3 Million USD | -9.96% |
| 2023 Q2 | -2.09 Million USD | -6.7% |
| 2023 Q1 | -1.96 Million USD | -10.56% |
| 2023 FY | -8.7 Million USD | -76.09% |
| 2022 Q2 | -1.1 Million USD | -125.32% |
| 2022 FY | -4.94 Million USD | -31.73% |
| 2022 Q1 | -490.62 Thousand USD | -51.89% |
| 2022 Q3 | -1.64 Million USD | -48.55% |
| 2022 Q4 | -1.77 Million USD | -8.18% |
| 2021 Q2 | -1.34 Million USD | -65.6% |
| 2021 Q1 | -814 Thousand USD | -59.15% |
| 2021 FY | -3.75 Million USD | -77.38% |
| 2021 Q3 | -1.03 Million USD | 23.02% |
| 2021 Q4 | -323.01 Thousand USD | 68.87% |
| 2020 FY | -2.11 Million USD | 55.55% |
| 2020 Q1 | -500.88 Thousand USD | 61.39% |
| 2020 Q2 | -519.17 Thousand USD | -3.65% |
| 2020 Q3 | -551.19 Thousand USD | -6.17% |
| 2020 Q4 | -511.48 Thousand USD | 7.2% |
| 2019 Q1 | -2.09 Million USD | -119.1% |
| 2019 Q4 | -1.29 Million USD | -109.27% |
| 2019 Q3 | -619.94 Thousand USD | 16.32% |
| 2019 Q2 | -740.88 Thousand USD | 64.71% |
| 2019 FY | -4.75 Million USD | -103.55% |
| 2018 FY | -2.33 Million USD | 84.95% |
| 2018 Q4 | -958.28 Thousand USD | -72.18% |
| 2018 Q3 | -556.56 Thousand USD | -73.14% |
| 2018 Q1 | -501.03 Thousand USD | -13.94% |
| 2018 Q2 | -321.45 Thousand USD | 35.84% |
| 2017 FY | -15.53 Million USD | -325.32% |
| 2017 Q1 | -331.34 Thousand USD | 77.13% |
| 2017 Q4 | -439.74 Thousand USD | -55.94% |
| 2017 Q3 | -282 Thousand USD | 98.05% |
| 2017 Q2 | -14.47 Million USD | -4269.57% |
| 2016 Q1 | -1.37 Million USD | -109.73% |
| 2016 FY | -3.65 Million USD | -133.24% |
| 2016 Q4 | -1.44 Million USD | -269.69% |
| 2016 Q3 | -391.93 Thousand USD | 10.27% |
| 2016 Q2 | -436.8 Thousand USD | 68.21% |
| 2015 Q2 | 263.2 Thousand USD | 129.73% |
| 2015 Q1 | -885.19 Thousand USD | -209.11% |
| 2015 FY | -1.56 Million USD | 95.77% |
| 2015 Q3 | -15.06 Million USD | -5825.5% |
| 2015 Q4 | 14.12 Million USD | 193.74% |
| 2014 Q4 | 811.26 Thousand USD | 754.62% |
| 2014 Q3 | 94.92 Thousand USD | 110.69% |
| 2014 Q2 | -887.77 Thousand USD | -4720.4% |
| 2014 FY | -36.99 Million USD | -42810.07% |
| 2014 Q1 | -18.41 Thousand USD | -19.91% |
| 2013 Q1 | -23.73 Thousand USD | 46.15% |
| 2013 Q2 | -25.48 Thousand USD | -7.39% |
| 2013 Q3 | -21.62 Thousand USD | 15.14% |
| 2013 Q4 | -15.35 Thousand USD | 28.99% |
| 2013 FY | -86.21 Thousand USD | 16.0% |
| 2012 Q3 | -23.59 Thousand USD | -67.02% |
| 2012 Q2 | -14.12 Thousand USD | 32.24% |
| 2012 Q1 | -20.84 Thousand USD | -45.58% |
| 2012 FY | -102.63 Thousand USD | 61.04% |
| 2012 Q4 | -44.07 Thousand USD | -86.8% |
| 2011 FY | -263.44 Thousand USD | 0.0% |
| 2011 Q1 | -170 Thousand USD | 0.0% |
| 2011 Q2 | -41.07 Thousand USD | 75.84% |
| 2011 Q3 | -35.75 Thousand USD | 12.94% |
| 2011 Q4 | -14.32 Thousand USD | 59.95% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acutus Medical, Inc. | -81.66 Million USD | 86.585% |
| Biotricity, Inc. | -14.09 Million USD | 22.271% |
| Cell MedX Corp. | -142.48 Thousand USD | -7588.682% |
| Dynatronics Corporation | -2.69 Million USD | -306.095% |
| Nemaura Medical Inc. | -14.14 Million USD | 22.543% |
| RetinalGenix Technologies Inc. | -2.09 Million USD | -423.954% |
| Sonendo, Inc. | -60.91 Million USD | 82.017% |
| Telesis Bio, Inc. | -47.72 Million USD | 77.044% |
| Talis Biomedical Corporation | -62 Million USD | 82.332% |
| Viveve Medical, Inc. | -22.02 Million USD | 50.264% |